IntrinsicIntrinsic
← All summaries

Cullinan Therapeutics, Inc.

CGEM
Financials & Chart →

Business Summary

Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing first- or best-in-class therapies for autoimmune diseases and cancer, leveraging expertise in T cell engagers. The company's core business model involves generating revenue through the development and potential commercialization of its product candidates, as well as through strategic collaborations and licensing agreements. Currently, Cullinan Therapeutics has no products approved for commercial sale and has not generated any revenue from product sales . The company's operations are primarily financed through the sale of equity securities and from licensing or selling rights to its product candidates, having received net proceeds of $842.2 million from equity financings, $275.0 million from the sale of its equity interest in its zipalertinib development subsidiary to Taiho, and $18.9 million in revenue from a previous license agreement as of December 31, 2025.

The company's product pipeline is divided into Immunology and Oncology programs. In Immunology, CLN-978 is a CD19xCD3 bispecific T cell engager being developed for autoimmune diseases, specifically systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's disease (SjD). Velinotamig is a BCMAxCD3 bispecific T cell engager licensed from Genrix for autoimmune diseases outside Greater China. In Oncology, CLN-049 is a FLT3xCD3 bispecific T cell engager for relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Zipalertinib (CLN-081/TAS6417) is an orally-available small-molecule EGFR inhibitor for EGFR exon 20 insertion mutations (EGFR ex20ins) non-small cell lung cancer (NSCLC), developed in collaboration with Taiho Pharmaceutical Co., Ltd.

For CLN-978, the company holds worldwide intellectual property rights . The portfolio includes five patent families, with composition claims expected to expire in 2040 and 2039 , and method of use claims expected to expire in 2044 and 2045 . A composition of matter patent was issued by the USPTO in September 2025, extending protection until at least 2042 . For Velinotamig, Cullinan holds worldwide intellectual property rights excluding Greater China , comprising four patent families. Composition claims are expected to expire between 2039 and 2045 , with a USPTO-issued composition of matter patent in December 2025 expiring in 2042 . Method of use claims are expected to expire in 2046 . For CLN-049, the company holds worldwide intellectual property rights through a development subsidiary with a 98% ownership interest as of December 31, 2025 . This includes one in-licensed patent family for compositions, expected to expire in 2039 , with an issued U.S. patent expiring in 2041 , and one owned patent family for methods of use, expected to expire in 2046 . For Zipalertinib, Taiho holds the intellectual property rights, with seven in-licensed patent families. A first family claiming specific EGFR-inhibiting compositions expires in 2034 , and five additional families for methods of use are expected to expire between 2037 and 2046 .

Key financial metrics for the fiscal year ended December 31, 2025, show a net loss of $219.9 million , compared to a net loss of $167.4 million in 2024. The accumulated deficit as of December 31, 2025, was $588.1 million . Total operating expenses for 2025 were $241.6 million , up from $196.9 million in 2024. Research and development expenses increased to $187.4 million in 2025 from $142.9 million in 2024. General and administrative expenses were $54.2 million in 2025, a slight increase from $54.0 million in 2024. Other income, primarily interest income, decreased to $22.2 million in 2025 from $29.7 million in 2024. The company reported no income tax expense or benefit in 2025 .

Year-over-year comparisons highlight a significant increase in research and development expenses by $44.5 million in 2025. This was primarily driven by a one-time upfront in-licensing fee for velinotamig of $20.0 million , increases in clinical development costs of $21.9 million , personnel costs relating to higher average headcount of $8.2 million , and equity-based compensation expense of $0.5 million . These increases were partially offset by decreases in preclinical costs of $3.7 million and chemistry, manufacturing and controls costs of $2.4 million . General and administrative expenses saw a modest increase of $0.2 million , mainly due to higher professional fees of $1.7 million and legal costs of $1.6 million , partially offset by decreases in equity-based compensation expense of $2.2 million and personnel costs of $1.0 million . Other income decreased by $7.7 million due to lower interest income.

Significant operational developments during the period include the initiation of Phase 1 clinical trials for CLN-978 in patients with active, moderate to severe SLE in December 2024 , in patients with active, difficult-to-treat RA in April 2025 , and in patients with active, moderate to severe Sjögren's disease in June 2025 . The company discontinued development of CLN-978 in B cell non-Hodgkin lymphoma (B-NHL) in early 2024 . Velinotamig was licensed from Genrix in June 2025 . For CLN-049, the FDA granted Fast Track designation in December 2025 for relapsed/refractory AML. Taiho completed a rolling submission of an NDA for zipalertinib in February 2026 seeking accelerated approval for previously treated EGFR ex20ins NSCLC. Taiho also completed enrollment of the REZILIENT3 Phase 3 clinical trial for zipalertinib in February 2026 . Several programs were discontinued: CLN-619 in May 2025 and November 2025 , CLN-617 in November 2025 , and CLN-418 in August 2024 with termination of the license agreement effective November 2024 .

Business Outlook

Cullinan Therapeutics plans to share initial clinical data for CLN-978 in SLE and RA in the second quarter of 2026 , with repeat dosing data in RA expected in the third quarter of 2026 . Initial clinical data for CLN-978 in Sjögren's disease is anticipated in the fourth quarter of 2026 . For velinotamig, initial clinical data from Genrix's Phase 1 clinical trial in China for autoimmune diseases will be shared in the fourth quarter of 2026 , with the intention to use this data to accelerate global clinical development. A clinical data update for CLN-049 from the dose escalation portion of the trial is planned for the second half of 2026 . The company also plans to begin enrolling dose expansion cohorts for CLN-049 in the second quarter of 2026 and expects to complete enrollment in the fourth quarter of 2026 to determine the recommended Phase 2 dose for a single-arm pivotal registrational trial. Additionally, a Phase 1/2 clinical trial evaluating CLN-049 as a potential frontline treatment in combination with standard-of-care for newly diagnosed AML patients is planned for initiation in the fourth quarter of 2026 . For zipalertinib, Taiho expects to obtain top-line results from the REZILIENT3 global Phase 3 clinical trial by the end of 2026 .

A major growth area for Cullinan is the broad potential of CLN-978 in autoimmune diseases. Academic and industry data suggest a CD19xCD3 T cell engager can achieve sustained improvements and durable remission in conditions like SLE and RA. CLN-978 is believed to be highly differentiated with potential advantages including off-the-shelf subcutaneous administration and the ability to lyse B cells expressing very low levels of CD19. The company is exploring broad development of CLN-978 across various autoimmune diseases. Another significant growth vector is advancing CLN-049 for a broad population of AML patients. The current AML treatment paradigm is fragmented, with limited broadly applicable options. CLN-049 binds both mutated and wild-type FLT3, expressed in over 80% of AML patients, offering potential to address a wide patient population without biomarker testing. The company plans to advance CLN-049 into dose expansion in relapsed AML and explore it as a frontline treatment in newly diagnosed AML.

Operationally, the company aims to unlock near-term non-dilutive financial benefits from zipalertinib through its collaboration with Taiho. Cullinan is eligible to receive $30.0 million and up to $100.0 million in payments from Taiho tied to U.S. regulatory approvals in second-line and first-line EGFR ex20ins NSCLC, respectively. The company is also eligible for 50% of any future pre-tax profits from potential U.S. sales of zipalertinib. These potential proceeds are planned to be used to advance priority programs, CLN-978 and CLN-049.

Regarding capital allocation, Cullinan Therapeutics had cash, cash equivalents, and short-term investments of $377.9 million , and long-term investments and interest receivable of $61.1 million as of December 31, 2025. The company believes its existing capital resources will be sufficient to fund anticipated operations into 2029 . The company has not paid or declared any cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain all available funds and future earnings for business development and expansion .

Risk Factors

Cullinan Therapeutics faces material risks including the inherent uncertainty and expense of preclinical and clinical development, where product candidates may fail to demonstrate adequate safety and efficacy, leading to delays or inability to obtain regulatory approval and commercialization. Difficulty in patient enrollment has caused, and could continue to cause, delays in clinical trials. Interim or preliminary clinical data may change materially upon full review, and open-label trial designs may exaggerate therapeutic effects. The company is early in its development efforts, with the exception of zipalertinib, and is substantially dependent on its lead product candidates; failure to advance these could materially harm the business. Product candidates may cause undesirable side effects, leading to delays, limited commercial potential, or negative consequences post-approval, including regulatory withdrawal or restrictive labeling. The small number of patients in early clinical trials makes results less reliable and may necessitate larger trials. Data from foreign clinical trials may not be accepted by the FDA or comparable foreign regulatory authorities, requiring additional costly and time-consuming trials. Developing product candidates in combination with other therapies exposes the company to additional risks, including the revocation of approval for the combination therapy or the need for additional trials if standard of care changes. Failure to successfully validate, develop, and obtain regulatory approval for required companion diagnostic tests could prevent or delay approval and limit commercial potential. The company has a limited operating history and has incurred significant losses, with an accumulated deficit of $588.1 million as of December 31, 2025, and expects to incur further losses, requiring substantial additional funding. Raising capital may dilute existing stockholders or require relinquishing rights to technologies or product candidates on unfavorable terms. The company's operations and financial condition could be adversely affected by global and regional economic conditions, including higher inflation or interest rates, recession, and trade policy changes. Business disruptions from natural or man-made disasters could harm future revenue and financial condition. The company relies on a limited number of employees, presenting operational challenges. Market opportunities and forecasts for product candidates may be inaccurate, and the actual market may be smaller than estimated. The company currently lacks a marketing and sales organization and relies on third parties for manufacturing, which could be disrupted by failures, raw material sourcing challenges, or geopolitical events in regions like China, where certain raw materials, drug substances, and/or drug products are sourced. Failure to obtain or maintain patent and other intellectual property protection, or challenges to existing rights, could allow competitors to commercialize similar products. Third-party claims of intellectual property infringement could be costly and time-consuming. Failure to comply with license agreements could result in loss of important rights. Inability to protect trade secrets could harm the business. Non-compliance with governmental regulations, including healthcare fraud and abuse laws, or data privacy laws like GDPR, could lead to significant penalties. The U.S. Supreme Court's Loper decision could increase regulatory uncertainty. Regulations regarding AI use and development are emerging globally, potentially imposing compliance costs and affecting business operations. The price of the company's stock is volatile, and principal stockholders and management own a significant percentage, potentially influencing stockholder approval matters. The company's ability to utilize net operating loss carryforwards of $312.6 million (federal) and $317.7 million (state) as of December 31, 2025, and research and development tax credit carryforwards of $8.7 million (federal) and $2.7 million (state) as of December 31, 2025, may be limited by ownership changes under Sections 382 and 383 of the Internal Revenue Code. Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change of control. Failure to maintain proper internal control over financial reporting could harm operating results.

Management Priorities

Management's message to shareholders emphasizes a strategy to accelerate potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, leveraging core expertise in T cell engagers. The company is committed to advancing its mission to deliver new standards of care for patients through a rigorous scientific approach and purposeful innovation. Key strategic priorities include exploring the broad potential of CLN-978 in autoimmune diseases, advancing CLN-049 for a broad population of AML patients, and unlocking the near-term non-dilutive financial benefits of zipalertinib. Management explicitly guides that initial clinical data for CLN-978 in SLE and RA will be shared in the second quarter of 2026 , with repeat dosing data in RA in the third quarter of 2026 , and initial clinical data in Sjögren's disease in the fourth quarter of 2026 . For velinotamig, initial clinical data from Genrix's Phase 1 trial in China will be shared in the fourth quarter of 2026 . A clinical data update for CLN-049's dose escalation is expected in the second half of 2026 , with dose expansion enrollment beginning in the second quarter of 2026 and completing in the fourth quarter of 2026 . A Phase 1/2 clinical trial for CLN-049 in frontline AML is planned for initiation in the fourth quarter of 2026 . Taiho expects top-line results for REZILIENT3 by the end of 2026 . Management also highlights the potential to receive up to $130.0 million from Taiho tied to EGFR ex20ins NSCLC U.S. regulatory milestones, with $30.0 million for second-line and up to $100.0 million for first-line approvals, and 50% of future pre-tax profits from potential U.S. sales of zipalertinib. These potential proceeds are intended to fund the development of CLN-978 and CLN-049.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Financing and Business Operations
  2. [2] Item 7, MD&A — Financing and Business Operations
  3. [3] Item 7, MD&A — Financing and Business Operations
  4. [4] Item 7, MD&A — Financing and Business Operations
  5. [5] Item 1, Business — Intellectual Property
  6. [6] Item 1, Business — Intellectual Property
  7. [7] Item 1, Business — Intellectual Property
  8. [8] Item 1, Business — Intellectual Property
  9. [9] Item 1, Business — Intellectual Property
  10. [10] Item 1, Business — Intellectual Property
  11. [11] Item 1, Business — Intellectual Property
  12. [12] Item 1, Business — Intellectual Property
  13. [13] Item 1, Business — Intellectual Property
  14. [14] Item 1, Business — Intellectual Property
  15. [15] Item 1, Business — Intellectual Property
  16. [16] Item 1, Business — Intellectual Property
  17. [17] Item 1, Business — Intellectual Property
  18. [18] Item 1, Business — Intellectual Property
  19. [19] Item 1, Business — Intellectual Property
  20. [20] Item 1, Business — Intellectual Property
  21. [21] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  22. [22] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  23. [23] Item 7, MD&A — Financing and Business Operations
  24. [24] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  25. [25] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  26. [26] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  27. [27] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  28. [28] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  29. [29] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  30. [30] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  31. [31] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  32. [32] Item 7, MD&A — Results of Operations Comparison of 2025 and 2024
  33. [33] Item 7, MD&A — Research and Development Expenses
  34. [34] Item 7, MD&A — Research and Development Expenses
  35. [35] Item 7, MD&A — Research and Development Expenses
  36. [36] Item 7, MD&A — Research and Development Expenses
  37. [37] Item 7, MD&A — Research and Development Expenses
  38. [38] Item 7, MD&A — Research and Development Expenses
  39. [39] Item 7, MD&A — Research and Development Expenses
  40. [40] Item 7, MD&A — General and Administrative Expenses
  41. [41] Item 7, MD&A — General and Administrative Expenses
  42. [42] Item 7, MD&A — General and Administrative Expenses
  43. [43] Item 7, MD&A — General and Administrative Expenses
  44. [44] Item 7, MD&A — General and Administrative Expenses
  45. [45] Item 7, MD&A — Other Income
  46. [46] Item 1, Business — CLN-978 Clinical Development
  47. [47] Item 1, Business — CLN-978 Clinical Development
  48. [48] Item 1, Business — CLN-978 Clinical Development
  49. [49] Item 1, Business — Discontinued Clinical Development in B Cell Non-Hodgkin Lymphoma ("B-NHL")
  50. [50] Item 1, Business — Velinotamig Overview
  51. [51] Item 1, Business — CLN-049 Background on AML and FLT3
  52. [52] Item 1, Business — Zipalertinib Clinical Development
  53. [53] Item 1, Business — Zipalertinib Clinical Development
  54. [54] Item 1, Business — Recently Discontinued Programs
  55. [55] Item 1, Business — Recently Discontinued Programs
  56. [56] Item 1, Business — Recently Discontinued Programs
  57. [57] Item 1, Business — Recently Discontinued Programs
  58. [58] Item 1, Business — Recently Discontinued Programs
  59. [59] Item 1, Business — CLN-978 Clinical Development
  60. [60] Item 1, Business — CLN-978 Clinical Development
  61. [61] Item 1, Business — CLN-978 Clinical Development
  62. [62] Item 1, Business — Velinotamig Clinical Development
  63. [63] Item 1, Business — CLN-049 Clinical Development
  64. [64] Item 1, Business — CLN-049 Clinical Development
  65. [65] Item 1, Business — CLN-049 Clinical Development
  66. [66] Item 1, Business — CLN-049 Clinical Development
  67. [67] Item 1, Business — Zipalertinib Clinical Development
  68. [68] Item 1, Business — Our Strategy
  69. [69] Item 1, Business — Our Strategy
  70. [70] Item 1, Business — Our Strategy
  71. [71] Item 7, MD&A — Financing and Business Operations
  72. [72] Item 7, MD&A — Financing and Business Operations
  73. [73] Item 1A, Risk Factors — We will require substantial additional funding to develop and commercialize our current and future product candidates.
  74. [74] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  75. [75] Item 7, MD&A — Financing and Business Operations
  76. [76] Item 1A, Risk Factors — Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  77. [77] Item 1A, Risk Factors — Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  78. [78] Item 1A, Risk Factors — Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  79. [79] Item 1A, Risk Factors — Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  80. [80] Item 1, Business — CLN-978 Clinical Development
  81. [81] Item 1, Business — CLN-978 Clinical Development
  82. [82] Item 1, Business — CLN-978 Clinical Development
  83. [83] Item 1, Business — Velinotamig Clinical Development
  84. [84] Item 1, Business — CLN-049 Clinical Development
  85. [85] Item 1, Business — CLN-049 Clinical Development
  86. [86] Item 1, Business — CLN-049 Clinical Development
  87. [87] Item 1, Business — CLN-049 Clinical Development
  88. [88] Item 1, Business — Zipalertinib Clinical Development
  89. [89] Item 1, Business — Zipalertinib Collaboration with Taiho Overview
  90. [90] Item 1, Business — Our Strategy
  91. [91] Item 1, Business — Our Strategy
  92. [92] Item 1, Business — Our Strategy

Analysis on 5/22/2026